Deep Track Capital, LP
13F Reported Value
ⓘ$6.1B
incl. option notional
Equity Holdings
ⓘ$4.8B
Option Notional
ⓘ$1.3B
$1.3B puts / $0 calls
Holdings
63
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Deep Track Capital, LP disclosed 63 positions worth $6.1B in its Form 13F-HR for Q1 2026 — $4.8B in common stock plus $1.3B of put/call option positions (reported at underlying notional value, not premium at risk), followed by $GH and $IMVT. During the quarter the fund opened 15 new positions and exited 7 — including a new stake in $ALMS and a full exit from $DVAX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Deep Track Capital, LP’s Form 13F-HR filing with the SEC under CIK 1856083.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
SPDR SERIES TRUST PUT
—Quality
$1.3B10,000,000 sh- 36.1#2,112
Quality
$308.4M3,338,241 sh - —
Quality
$286.3M11,526,971 sh - 40.8
Quality
$252.5M3,600,000 sh - —
Quality
$249.9M4,300,000 sh - —
Quality
$206.3M4,279,848 sh - 36.6
Quality
$185.9M1,100,000 sh - 63.9
Quality
$182.3M4,532,374 sh - 12.8
Quality
$166.7M19,686,282 sh - —
Quality
$165.2M4,106,067 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| SPDR SERIES TRUST PUT | — | $1.3B | 10,000,000 |
 Guardant Health, Inc.$GH | 36.1#2,112 | $308.4M | 3,338,241 |
 Immunovant, Inc.$IMVT | — | $286.3M | 11,526,971 |
 Tarsus Pharmaceuticals, Inc.$TARS | 40.8 | $252.5M | 3,600,000 |
 Vaxcyte, Inc.$PCVX | — | $249.9M | 4,300,000 |
 Structure Therapeutics Inc.$GPCR | — | $206.3M | 4,279,848 |
 Axsome Therapeutics, Inc.$AXSM | 36.6 | $185.9M | 1,100,000 |
 Apellis Pharmaceuticals, Inc.$APLS | 63.9 | $182.3M | 4,532,374 |
 OCULAR THERAPEUTIX, INC$OCUL | 12.8 | $166.7M | 19,686,282 |
 Vera Therapeutics, Inc.$VERA | — | $165.2M | 4,106,067 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Deep Track Capital, LP's 63 positions.
Showing top 10 of 63 holdings.
Sector Allocation
Healthcare
$4.8B
Full Holdings — Deep Track Capital, LP (Q1 2026)
All 63 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | — | SPDR SERIES TRUST | $1.3B | — | +0% | — |
| 2 | $GH | Guardant Health, Inc. | $308.4M | 6.4% | +19% | 36.1 |
| 3 | $IMVT | Immunovant, Inc. | $286.3M | 5.9% | +0% | — |
| 4 | $TARS | Tarsus Pharmaceuticals, Inc. | $252.5M | 5.2% | +20% | 40.8 |
| 5 | $PCVX | Vaxcyte, Inc. | $249.9M | 5.2% | +8% | — |
| 6 | $GPCR | Structure Therapeutics Inc. | $206.3M | 4.3% | +4% | — |
| 7 | $AXSM | Axsome Therapeutics, Inc. | $185.9M | 3.8% | -4% | 36.6 |
| 8 | $APLS | Apellis Pharmaceuticals, Inc. | $182.3M | 3.8% | -42% | 63.9 |
| 9 | $OCUL | OCULAR THERAPEUTIX, INC | $166.7M | 3.4% | +144% | 12.8 |
| 10 | $VERA | Vera Therapeutics, Inc. | $165.2M | 3.4% | +46% | — |
| 11 |  $ALMS | ALUMIS INC. | $149.2M | 3.1% | NEW | 9.2 |
| 12 |  $IONS | IONIS PHARMACEUTICALS INC | $146.4M | 3.0% | +15% | 37.1 |
| 13 |  $NUVL | Nuvalent, Inc. | $141.0M | 2.9% | NEW | — |
| 14 |  $ALKS | Alkermes plc. | $127.0M | 2.6% | +80% | — |
| 15 |  $CNTA | Centessa Pharmaceuticals plc | $125.4M | 2.6% | +58% | — |
| 16 |  $MLTX | MoonLake Immunotherapeutics | $119.5M | 2.5% | +39% | — |
| 17 |  $MAZE | Maze Therapeutics, Inc. | $103.8M | 2.1% | -18% | 19.7 |
| 18 |  $ORKA | Oruka Therapeutics, Inc. | $99.8M | 2.1% | -6% | — |
| 19 |  $NRIX | Nurix Therapeutics, Inc. | $98.4M | 2.0% | -10% | 13.2 |
| 20 |  $GMAB | GENMAB A/S | $98.3M | 2.0% | NEW | — |
| 21 |  $CYTK | CYTOKINETICS INC | $90.6M | 1.9% | -59% | 28 |
| 22 |  $GRAL | GRAIL, Inc. | $89.0M | 1.8% | +68% | 31.9 |
| 23 |  $LBRX | LB PHARMACEUTICALS INC | $82.7M | 1.7% | +0% | — |
| 24 |  $MBX | MBX Biosciences, Inc. | $82.3M | 1.7% | -15% | — |
| 25 |  $BCAX | Bicara Therapeutics Inc. | $80.8M | 1.7% | +55% | — |
| 26 |  $CMPS | COMPASS Pathways plc | $67.3M | 1.4% | +66% | — |
| 27 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $65.0M | 1.3% | -50% | 74.1 |
| 28 |  $BBIO | BridgeBio Pharma, Inc. | $62.5M | 1.3% | +4% | 31.7 |
| 29 |  $IMCR | Immunocore Holdings plc | $58.2M | 1.2% | -4% | — |
| 30 |  $TNGX | Tango Therapeutics, Inc. | $57.5M | 1.2% | +12% | 26.9 |
| 31 |  $DFTX | Definium Therapeutics, Inc. | $56.7M | 1.2% | NEW | — |
| 32 |  $TERN | Terns Pharmaceuticals, Inc. | $56.6M | 1.2% | +40% | — |
| 33 |  $GERN | GERON CORP | $47.3M | 1.0% | -2% | — |
| 34 |  $ANIP | ANI PHARMACEUTICALS INC | $46.1M | 0.9% | +26% | 68.6 |
| 35 |  $CRMD | CorMedix Inc. | $42.6M | 0.9% | +19% | 75.5 |
| 36 |  $ATAI | Atai Beckley N.V. | $42.5M | 0.9% | +157% | — |
| 37 |  $CLDX | Celldex Therapeutics, Inc. | $40.7M | 0.8% | -32% | 13.2 |
| 38 |  $COGT | Cogent Biosciences, Inc. | $38.5M | 0.8% | +121% | — |
| 39 |  $CRVS | Corvus Pharmaceuticals, Inc. | $36.5M | 0.8% | NEW | — |
| 40 |  $DYN | Dyne Therapeutics, Inc. | $36.3M | 0.8% | -25% | — |
| 41 |  $SLNO | SOLENO THERAPEUTICS INC | $36.1M | 0.8% | +8% | 46.3 |
| 42 |  $ACRS | Aclaris Therapeutics, Inc. | $35.0M | 0.7% | NEW | 9.2 |
| 43 |  $MANE | Veradermics, Inc | $31.6M | 0.7% | NEW | — |
| 44 |  $VSTM | Verastem, Inc. | $30.4M | 0.6% | +0% | 40.8 |
| 45 |  $ENGN | enGene Therapeutics Inc. | $29.8M | 0.6% | +0% | — |
| 46 |  $VRDN | Viridian Therapeutics, Inc.\DE | $27.3M | 0.6% | -45% | 30.5 |
| 47 |  $XFOR | X4 Pharmaceuticals, Inc | $26.2M | 0.5% | +26% | 29.3 |
| 48 |  $SLDB | Solid Biosciences Inc. | $25.7M | 0.5% | NEW | — |
| 49 |  $ENTA | ENANTA PHARMACEUTICALS INC | $24.7M | 0.5% | +0% | 15.5 |
| 50 |  $APGE | Apogee Therapeutics, Inc. | $24.0M | 0.5% | NEW | — |
| 51 |  $KURA | Kura Oncology, Inc. | $21.5M | 0.4% | NEW | 9.1 |
| 52 |  $IPSC | Century Therapeutics, Inc. | $21.4M | 0.4% | NEW | 43.5 |
| 53 |  $BEAM | Beam Therapeutics Inc. | $19.6M | 0.4% | NEW | 12.1 |
| 54 |  $CNTX | Context Therapeutics Inc. | $19.4M | 0.4% | +0% | — |
| 55 |  $PSNL | Personalis, Inc. | $19.1M | 0.4% | NEW | 15.7 |
| 56 |  $JANX | Janux Therapeutics, Inc. | $16.5M | 0.3% | +1225% | 24.8 |
| 57 |  $PMN | ProMIS Neurosciences Inc. | $10.6M | 0.2% | NEW | — |
| 58 |  $CBIO | CRESCENT BIOPHARMA, INC. | $8.3M | 0.2% | +0% | 28 |
| 59 |  $IVA | Inventiva S.A. | $6.8M | 0.1% | +149% | — |
| 60 |  $LRMR | Larimar Therapeutics, Inc. | $6.8M | 0.1% | NEW | — |
| 61 |  $HELP | CYBIN INC. | $6.3M | 0.1% | -29% | — |
| 62 |  $BLLN | BillionToOne, Inc. | $3.9M | 0.1% | +0% | — |
| 63 |  $ALGS | Aligos Therapeutics, Inc. | $3.3M | 0.1% | +0% | — |
New Positions (15)
$ALMS ALUMIS INC.$149.2M$NUVL Nuvalent, Inc.$141.0M$GMAB GENMAB A/S$98.3M$DFTX Definium Therapeutics, Inc.$56.7M$CRVS Corvus Pharmaceuticals, Inc.$36.5M$ACRS Aclaris Therapeutics, Inc.$35.0M$MANE Veradermics, Inc$31.6M$SLDB Solid Biosciences Inc.$25.7M$APGE Apogee Therapeutics, Inc.$24.0M$KURA Kura Oncology, Inc.$21.5M$IPSC Century Therapeutics, Inc.$21.4M$BEAM Beam Therapeutics Inc.$19.6M$PSNL Personalis, Inc.$19.1M$PMN ProMIS Neurosciences Inc.$10.6M$LRMR Larimar Therapeutics, Inc.$6.8M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Deep Track Capital, LP including:
Track Deep Track Capital, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Deep Track Capital, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Deep Track Capital, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Deep Track Capital, LP (SEC CIK: 1856083), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Deep Track Capital, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.